

December 2007

In This Issue

2007 ASCO Annual Meeting & 2007 Gastrointestinal Cancers Symposium

Cooperative Group Abstracts:

- [Breast Cancer](#)
- [CNS Cancer](#)
- [Gastrointestinal Cancer](#)
- [Genitourinary Cancer](#)
- [Gynecologic Cancer](#)
- [Head and Neck Cancer](#)
- [Leukemia, Myelodysplasia, and Transplantation](#)
- [Lymphoma and Plasma Cell Disorders](#)
- [Lung Cancer](#)
- [Melanoma/Skin Cancers](#)
- [Sarcoma/Bone and Soft Tissue Cancers](#)
- [Other Cancer](#)

NCI/CTEP Abstracts & Activities:

- [DCTD/DCP Abstracts](#)
- [DCTD/DCP Activities](#)



The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in July (post AMI, AACR, ACR, ASCO and SNM) and in January (post SMI, ISOQOL, ASTRO, RSNA and ASH) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention. This pilot issue includes the 2007 ASCO Annual Meeting and GI Cancers Symposium and Cancer Therapy Evaluation Program activities.

Research Highlights in this Issue:


Addition of two courses of arsenic trioxide consolidation following remission induction significantly improves event-free survival in acute promyelocytic leukemia (APL).

Abstract 2 (Leukemia, Myelodysplasia, and Transplantation/CALGB/Powell et al.)

Adjuvant imatinib mesylate increases recurrence free survival in patients with completely resected localized primary GIST. *Abstract 10079* (Gastrointestinal Cancer/ACOSOG/DeMatteo et al.)



ACOSOG



Cooperative Group Abstracts

Breast Cancer

CALGB

Kaufman PA, Broadwater G, Lezon-Geyda K, Dressler LG, Berry D, Friedman P, Winer EP, Hudis C, Ellis, Seidman AD, Harris LN: CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.1009.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/1009

Protocol(s): CALGB-9480, CALGB-150002

ECOG

Badve SS, Baehner FL, Gray R, Childs B, Maddala T, Rowley S, Shak S, Davidson N, Goldstein LJ, Sparano J: Concordance of local and central laboratory hormone and HER2 receptor status in ECOG 2197. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.21022.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/21022

Protocol(s): E2197

Goldstein LJ, Gray R, Childs BH, Watson D, Rowley S, Shak S, Badve S, Davidson NE, Sledge GW, Sparano JA: Prognostic utility of 21-gene assay in hormone receptor (HR) positive operable breast cancer and 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): An analysis of Intergroup Trial E2197. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.526.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/526

Protocol(s): E2197

Gor PP, Gray RJ, Horn M, Rebbeck TR, Gimotty PA, Aplenc R, Pins M, Tallman MS, DeMichele A: Association of polymorphic drug metabolizing enzymes (DME) with outcomes in breast cancer patients treated on the ECOG 2190/Intergroup 0121 (E2190/Int0121) study. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.596.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/596

Protocol(s): E2190

Moulder SL, O'Neill A, Arteaga C, Pins C, Sparano J, Sledge G, Davidson N; Eastern Cooperative Oncology Group: Final Results of ECOG1100: A phase I/II study of combined blockade of the ErbB receptor network in patients with HER2- overexpressing metastatic breast cancer (MBC). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.1033.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/1033

Protocol(s): E1100

Sparano JA, Wang M, Martino S, Jones V, Perez E, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.516.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/516

Protocol(s): E1199

Wang M, Gradishar WJ, Sparano JA, Perez EA, Sledge G: A phase II trial of capecitabine (C) in combination with the farnesyltransferase inhibitor (FTI), tipifarnib (T), in patients (pt) with metastatic breast cancer (MBC): ECOG trial 1103. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.1036.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/1036

Protocol(s): E1103

NCCTG

Kutteh LA, Hobday T, Jaffe A, LaPlant B, Hillman D, Kaufman P, Davidson N, Martino S, Moreno A, et al.: A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.579.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/579

Protocol(s): N9831

Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM, Perez EA: NCCTG phase II trial N0531 of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.1048.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/1048

Protocol(s): N0531

NCIC Clinical Trials Group

Burnell MJ, Levine MN, Chapman JA, Bramwell V, Vandenberg T, Chalchal HI, Albain K, Perez E, Rugo H, Pritchard K: A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.550.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/550

Protocol(s): NCIC-MA.21

Chapman JW, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, Palmer M, Yu C, Goss PE: Competing causes of death in NCIC CTG MA.17, a placebo-controlled trial of letrozole as extended adjuvant therapy for breast cancer patients. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.540.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/540

Protocol(s): JMA17

NSABP

Anderson SJ, Bryant JL, Jeong J, Tang G, Costantino JP, Mamounas E, Geyer CE, Wolmark N: Rethinking the role of nodal status in TNM staging of node-positive breast cancer. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.10584.

http://meeting.jco.org/cgi/content/full/25/18_suppl/10584/T1

Protocol(s): NSABP-B-07, NSABP-B-22, NSABP-B-08, NSABP-B-16, NSABP-B-15, NSABP-B-12, NSABP-B-09, NSABP-B-05, NSABP-B-10, NSABP-B-28, NSABP-B-25, NSABP-B-31, NSABP-B-11

Paik S, Kim C, Jeong J, Geyer CE, Romond EH, Mejia-Mejia O, Mamounas EP, Wickerham D, Costantino JP, Wolmark N: Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.511.

http://meeting.jco.org/cqi/content/abstract/25/18_suppl/511

Protocol(s): NSABP-B-31

Perez EA, Romond EH, Suman VJ, Jeong J, Davidson NE, Geyer CE, Martino S, Mamounas EP, Kauffman PA, Wolmark N: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.512.

http://meeting.jco.org/cqi/content/abstract/25/18_suppl/512

Protocol(s): N9831, NSABP-B-31

Rastogi P, Jeong J, Geyer CE, Costantino JP, Romond EH, Ewer MS, Keefe DL, Levine T, Swain SM, Wolmark N: Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)paclitaxel (T) vs. ACT with trastuzumab (H). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.LBA513.

http://meeting.jco.org/cqi/content/abstract/25/18_suppl/LBA513

Protocol(s): NSABP-B-31

Ross DT, Kim C, Tang G, Mejia OM, Beck RA, Ring BZ, Seitz RS, Paik S, Costantino JP, Wolmark N: Chemosensitivity and stratification by a five monoclonal antibody IHC test in the NSABP B20 trial. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.529.

http://meeting.jco.org/cqi/content/abstract/25/18_suppl/529

Protocol(s): NSABP-B-20

Wapnir I, Dignam J, Julian TB, Land S, Mamounas EP, Anderson S, Fourchette V, Costantino J, Wolmark N: Long-term outcomes after invasive breast tumor recurrence (IBTR) in women with DCIS in NSABP B-17 and B-24. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.520.

http://meeting.jco.org/cqi/content/abstract/25/18_suppl/520

Protocol(s): NSABP-B-24, NSABP-B-17

SWOG

Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingston R, Martino S, Perez E, Sher D, et al.: Screening for clonal hematopoiesis as a predictive marker for development of t-AML following adjuvant therapy for breast cancer (S0012). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.11051.

http://meeting.jco.org/cqi/content/abstract/25/18_suppl/11051

Protocol(s): S0012

CNS Cancer

NCCTG

Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Giannini C, Hardwick JS, Moore DF Jr, Zwiebel JA, Buckner JC: N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.2004.

http://meeting.jco.org/cqi/content/abstract/25/18_suppl/2004

Protocol(s): N047B

Lamborn K, Wu W, Prados M, Jaeckle K, Chang S, Novotny P, Buckner J: Joint NABTC + NCCTG prognostic factors analysis for high grade recurrent glioma. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.2075.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/2075

Protocol(s): Multiple Trials

Gastrointestinal Cancer

ACOSOG

DeMatteo R, Owzar K, Maki R, Pisters P, Blackstein M, Antonescu C, Blanke C, Demetri G, von Mehren M, Ballman K: Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. American Society of Clinical Oncology Annual Meeting, Chicago, IL, Jun, 2007. 10079.

Protocol(s): ACOSOG-Z9001

CALGB

Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLeod HL, Mulcahy MF, et al.: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients with advanced pancreatic cancer: A preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4508.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4508

Protocol(s): CALGB-80303

Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz L, Willett W, Mayer RJ, Fuchs CS: The impact of dietary patterns on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4019.

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/4019

Protocol(s): C89803

Romanus D, Archer L, Wang X, Goldberg R, Mulcahy M, Kindler H, Schrag D: Does health-related quality of life (HRQL) improve for patients who respond to chemotherapy? Analysis of patients with advanced pancreas cancer (APC) receiving gemcitabine on Cancer and Leukemia Group B (CALGB) study #80303. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.9008.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9008

Protocol(s): CALGB-80303

Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM: N9741: Survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4067.

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/4067

Protocol(s): N9741

Schrag D, Archer L, Wang X, Romanus D, Mulcahy M, Goldberg R, Kindler H: A patterns-of-care study of post-progression treatment (Rx) among patients (pts) with advanced pancreas cancer (APC) after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4524.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4524

Protocol(s): CALGB-80303

ECOG

Burtness BA, Powell M, Berlin J, Liles D, Chapman A, Mitchell E, Benson AB and Eastern Cooperative Oncology Group: Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r): Eastern Cooperative Oncology. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4519.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4519

Protocol(s): E8200

Catalano PJ, Mitchell EP, Giantonio BJ, Meropol NJ, Benson AB: Outcomes differences for African Americans and Caucasians treated with bevacizumab, FOLFOX4 or the combination in patients with metastatic colorectal cancer (MCRC): Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4100.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4100

Protocol(s): E3200

Kleinberg L, Powell ME, Forastiere A, Keller S, Anne P, Benson AB: E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged adenocarcinoma of the esophagus. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4533.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4533

Protocol(s): E1201

NCCTG

Alberts S, Mahoney MR, Donohue JH, Roh MS, Green EM, Sargent DJ, Wagman LD, Bolton JS: Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4057.

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/4057

Protocol(s): N9741

Alberts SR, Foster NR, McWilliams RR, Quevedo FJ, Marschke RF, Kugler JW, Friedman EL, Jaslowski AJ, Sande JR: NCCTG phase I/II trial (N9943) of gemcitabine and pemetrexed in patients with unresectable or metastatic biliary tract carcinoma and gallbladder carcinoma--Interim results. 2007 Gastrointestinal Cancers Symposium, Orlando, FL, Jan, 2007. Abst.149.

Protocol(s): N9943

Alberts SR, Morlan BW, Kim GP, Pitot HC, Quevedo FJ, Dakhil SR, Gross HM, Merchan JR, Roberts LR: NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)-- Interim review of toxicity. 2007 Gastrointestinal Cancers Symposium, Orlando, FL, Jan, 2007.

Abst.186.

Protocol(s): N044J

Campbell ME, Grothey A, D. J. Sargent DJ, Goldberg RM: Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in advanced colorectal cancer (ACRC) - lessons learned from N9741. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4080.

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/4080

Protocol(s): N9741

Goldberg RM, Köhne CH, Seymour MT, de Gramont A, Porschen R, Saltz L, Rougier P, Tournigand C, Grothey A, Sargent DJ: A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4011.

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/4011

Protocol(s): Multiple Trials

Haddock MG, Kim GP, Foster NR, Bollinger J, Stella PJ, Kugler JW, Dakhi SRI, Alberts SR, Martenson JA: Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU) and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer (NCCTG 0349). 2007 Gastrointestinal Cancers Symposium, Orlando, FL, Jan, 2007. Abst.176.

Protocol(s): N0349

Kim GP, Alberts SR, Oberg AL, Foster NR, Grothey A, Flynn PJ, Schaefer PL, Wiesenfeld M, Campbell D, Hedrick E: Phase II trial of bevacizumab, gemcitabine, and oxaliplatin in patients with metastatic pancreatic adenocarcinoma. 2007 Gastrointestinal Cancers Symposium, Orlando, FL, Jan, 2007. Abst.169.

Protocol(s): N034A

Kim GP, Oberg AL, Foster NR, Jaslowski A, Flynn PJ, Campbell D, Hedrick E, Gray L, Grothey A, Alberts S: Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4553.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4553

Protocol(s): N034A

McWilliams RR, Foster NR, Quevedo FJ, Marschke RF, Kugler JW, Friedman EL, Jaslowski AJ, Sande JR, Alberts SR: NCCTG phase I/II trial (N9943) of gemcitabine and pemetrexed in patients with biliary tract or gallbladder carcinoma: Phase II results. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4578.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4578

Protocol(s): N9943

O'Connell MJ: Survival following recurrence in patients with adjuvant colon cancer: Findings from the 20,800-patient ACCENT dataset. 2007 Gastrointestinal Cancers Symposium, Orlando, FL, Jan, 2007. Abst.4009.

Protocol(s): NSABP-C-07, NSABP-C-05, NSABP-C-03, NSABP-C-06, NSABP-C-04, NSABP-C-02, NSABP-C-01

Sargent DJ for the Adjuvant Colon Cancer Endpoints (ACCENT) Group: Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: Lessons from the 20,800-patient (pt) ACCENT dataset. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4008.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4008

Protocol(s): NSABP-C-07, NSABP-C-03, NSABP-C-01, NSABP-C-02, NSABP-C-05, NSABP-C-04, NSABP-C-06

Yothers G, Blackstock W, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti J, Dignam J, Sargent DJ: Outcomes in white (W) patients (pts) and those of African (A) descent receiving adjuvant therapy for colon cancer (CC). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4017.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4017

Protocol(s): NSABP-C-04, NSABP-C-01, NSABP-C-07, NSABP-C-05, NSABP-C-06, NSABP-C-02, NSABP-C-03

NSABP

O'Connell MJ: Survival following recurrence in patients with adjuvant colon cancer: Findings from the 20,800-patient ACCENT dataset. 2007 Gastrointestinal Cancers Symposium, Orlando, FL, Jan, 2007. Abst.4009.

Protocol(s): NSABP-C-07, NSABP-C-06, NSABP-C-04, NSABP-C-02, NSABP-C-01, NSABP-C-05, NSABP-C-03

Sargent DJ for the Adjuvant Colon Cancer Endpoints (ACCENT) Group: Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: Lessons from the 20,800-patient (pt) ACCENT dataset. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4008.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4008

Protocol(s): NSABP-C-07, NSABP-C-02, NSABP-C-04, NSABP-C-05, NSABP-C-06, NSABP-C-03, NSABP-C-01

Yothers G, Blackstock W, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti J, Dignam J, Sargent DJ: Outcomes in white (W) patients (pts) and those of African (A) descent receiving adjuvant therapy for colon cancer (CC). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4017.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/4017

Protocol(s): NSABP-C-07, NSABP-C-02, NSABP-C-06, NSABP-C-03, NSABP-C-04, NSABP-C-05, NSABP-C-01

RTOG

Abrams R, Winter K, Regine W, Safran H, Hoffman J, Konski A, Benson A, Macdonald J, Rich T, Willett C: Correlation of RTOG 9704 (adjuvant therapy (rx) of pancreatic adenocarcinoma (pan ca)) radiation therapy quality assurance scores (RTQASc) with survival (S). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4523.

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vqnextoid=76f8201eb61a7010VqnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=31938

Protocol(s): RTOG-97-04

Berger A, Winter K, Hoffman J, Regine W, Abrams R, Safran H, Konski A, Benson III A, MacDonald J, Willet C: Post-resection CA 19-9 predicts overall survival (OS) in patients treated with adjuvant chemoradiation: A secondary endpoint of RTOG 9704. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4522.

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vqnextoid=76f8201eb61a7010VqnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=33400

Protocol(s): RTOG-97-04

Efstathiou J, Bae K, Shipley W, Hanks G, Pilepich M, Sandler H, Smith M: Obesity and prostate cancer-specific mortality following radiation therapy and androgen suppression for locally advanced prostate cancer: An analysis of RTOG 85-31. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.112.

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vqnextoid=76f8201eb61a7010VqnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=46&abstractID=20241

Protocol(s): RTOG-85-31

Konski A, Winter K, John M, Flam M, Krieg R, Pinover W, Myerson R, Willett C: Evaluation of planned treatment breaks during radiation therapy for anal cancer: Update of Radiation Therapy Oncology Group (RTOG) 92-08. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.297.

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vqnextoid=76f8201eb61a7010VqnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=45&abstractID=10252

Protocol(s): RTOG-92-08

Zachariah B, James J, Gwede C, Ajani J, Chin L, Donath D, Kane B, Rotman M, Berk L: RTOG 0315: A randomized, double-blind, placebo-controlled phase III study to determine the efficacy of octreotide acetate in preventing or reducing the severity of chemoradiation-induced diarrhea in patients with anal or rectal cancer. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4032.

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vqnextoid=76f8201eb61a7010VqnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=31494

Protocol(s): RTOG-0315

SWOG

Chang H, Azuma M, Goldman B, Nagashima F, Iqbal S, Danenberg K, Benedetti J, Zhang W, Blanke C, Lenz H: Gene expression levels of HER2 and IL-8 and polymorphism in IL-8 associated with clinical outcome in advanced or metastatic gastric cancer treated with lapatinib in SWOG 0413 trial. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4647.

http://meeting.jco.org/cqi/content/abstract/25/18_suppl/4647

Protocol(s): S0413

El-Khoueiry AB, Rankin C, Lenz HJ, Philip P, Rivkin SE and Blanke CD: SWOG 0514: A phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4639.

http://meeting.jco.org/cqi/content/abstract/25/18_suppl/4639

Protocol(s): S0514

Iqbal S, Goldman B, Lenz HJ, Fenoglio-Preiser CM and Blanke CD: S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.4621.

http://meeting.jco.org/cqi/content/abstract/25/18_suppl/4621

Protocol(s): S0413

Philip PA, Benedetti J, Fenoglio-Preiser C, Zalupski M, Lenz H, O'Reilly E, Wong R, Atkins J, Abruzzese J, Blanke C: Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.LBA4509.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/LBA4509

Protocol(s): S0205

Genitourinary Cancer

ECOG

Li S, Dreicer R, Roth B, Manoloa J, Cooney M, Wilding G: Phase II trial of pemetrexed disodium and gemcitabine in advanced carcinoma of the urothelium (E4802): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.5079.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/5079

Protocol(s): E4802

Manola J, Carducci M, Nair S, Liu G, Rousey S, Wilding G: Phase II ECOG trial of atrasentan in advanced renal cell carcinoma. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.5102.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/5102

Protocol(s): E6800

NCCTG

Loprinzi CL, Khoyratty BS, Dueck A, Barton DL, Jafar S, Rowland KM Jr, Atherton PJ, Marsa GW, Krook J, Kottschade L: Gabapentin for hot flashes in men: NCCTG trial N00CB. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.9005.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9005

Protocol(s): N00CB

RTOG

Efstathiou J, Bae K, Shipley W, Hanks G, Pilepich M, Sandler H, Smith M: Body mass index and mortality in men treated for locally advanced prostate cancer: An analysis of RTOG 85-31. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.5128.

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vqnextoid=76f8201eb61a7010VqnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=32191

Protocol(s): RTOG-85-31

Souhami L, Bae K, Pilepich M, Sandler H: The impact of the duration of adjuvant hormonal therapy in patients with unfavorable prognosis prostate cancer treated with radiotherapy: Secondary analysis of RTOG 85-31. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.5062.

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vqnextoid=76f8201eb61a7010VqnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=31501

Protocol(s): RTOG-85-31

Valicenti R, Bae K, Michalski J, Shipley W, Sandler H, Cox J: Does adjuvant hormonal therapy improve freedom from biochemical relapse in prostate cancer patients receiving dose- escalated radiation therapy? An analysis of RTOG 94-06. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.297.
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vqnextoid=76f8201eb61a7010VqnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=46&abstractID=20134
 Protocol(s): RTOG-94-06

SWOG

Goldman BH, Lara PN, Beer TM, Mack PC, Drabkin HA, Holland WS, Crawford E and Ryan CW: Clinical and molecular factors predictive of outcome with first-line sorafenib-based therapy in advanced renal carcinoma (RCC): An analysis of SWOG 0412. J Clin Oncol 2007; 25(18S(Jun 20 Supl)):Abst.5108.
http://meeting.jco.org/cqi/content/abstract/25/18_suppl/5108
 Protocol(s): S0412

Pan C, Hussey M, Lara P, Mack PC, Nagle RB, Dutcher J, Samlowski W, Clark J, Crawford ED, et al.: Phase II trial of the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (pts) with advanced papillary renal cell carcinoma (pRCC)--SWOG S0317. J Clin Oncol 2007; 25(18S(Jun 20 Supl)):Abst.15516.
http://meeting.jco.org/cqi/content/abstract/25/18_suppl/15516
 Protocol(s): S0317

Van Veldhuizen PJ, Hussey M, Lara PN, Gumerlock PH, Clark J, Lange MK and Crawford ED: A phase II study of IV gemcitabine (G) and oral capecitabine (C) in patients (pts) with advanced renal cell cancer (RCC): Results of Southwest Oncology Group study 0312. J Clin Oncol 2007; 25(18S(Jun 20 Supl)):Abst.15562.
http://meeting.jco.org/cqi/content/abstract/25/18_suppl/15562
 Protocol(s): S0312

Gynecologic Cancer

GOG

Han ES, Burger RA, Randall-Whitis L, Parmakhtiar B, Darcy K, Sill M, Connelly P, Monk BJ, Fruehauf JP: Relationship of angiogenesis biomarkers and clinical response to bevacizumab (Bev) in persistent or recurrent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC) patients treated in a Phase II Gynecologic Oncology Group study. J Clin Oncol 2007; 25(18S(Jun 20 Supl)):Abst.21021.
http://meeting.jco.org/cqi/content/abstract/25/18_suppl/21021
 Protocol(s): GOG-0218

Krasner CN, Seiden MV, Fuller AF, Jr, Supko JG, Roche M, Kendal DLI, Lee J, Berkowitz R, Berlin S, Matulonis UA: Results of all-intraperitoneal carboplatin and paclitaxel regimen shows good tolerability and efficacy for advanced ovarian cancer. J Clin Oncol 2007; 25(18S(Jun 20 Supl)):Abst.5521.
http://meeting.jco.org/cqi/content/abstract/25/18_suppl/5521
 Protocol(s): GOG-0172

Krivak TC, Darcy KM, Tian C, Baysal BE, Armstrong DK, Gallion HH, Deloia JA: Relationship between polymorphisms in codon 118 and C8092A in ERCC1 and clinical outcome in optimally-resected, stage III epithelial ovarian cancer treated with intraperitoneal or intravenous cisplatin and paclitaxel: A gynecologic oncology. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.21050.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/21050

Protocol(s): GOG-0172

Moore DH, Tian C, Monk BJ, Long HJ, Omura G: Factors predictive of response to cisplatin-based chemotherapy in stage IVB persistent or recurrent cervical carcinoma: A multivariate analysis of three Gynecologic Oncology Group trials. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.5534.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/5534

Protocol(s): GOG-0179, GOG-0169

Schink JC, Bamlett-Sherman T, Anastos LM: Outpatient intraperitoneal chemotherapy for ovarian cancer chemotherapy—A comparison of reimbursement for intraperitoneal versus intravenous therapy. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.16027.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/16027

Protocol(s): GOG-0172

SWOG

Alberts DS, Liu PY, Wilczynski S, Clouser M, Lopez A, Lange M, Lanzotti V and Markman M: Phase III randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy: Southwest Oncology Group Protocol S0200. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.5551.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/5551

Protocol(s): S0200

Head and Neck Cancer

ECOG

Fakhry C, Westra W, Li S, Cmelak A, Ridge J, Pinto H, Forastiere A, Gillison M: Prognostic significance of human papillomavirus (HPV) tumor status for patients with head and neck squamous cell carcinoma (HNSCC) in a prospective, multi-center phase II clinical trial. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.6000.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/6000

Protocol(s): E2399

Wanebo HJ, Ghebremichael M, Burtness B, Spencer S, Ridge J, Forastiere A: Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.6015.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/6015

Protocol(s): E2303

SWOG

Adelstein DJ, Moon J, Hanna E, Shankar Giri PG, Mills GM, Wolf GT and Urba SG: S0216: A Southwest Oncology Group (SWOG) phase II trial of docetaxel (T), cisplatin (P), and fluorouracil (F) induction followed by accelerated fractionation/concomitant boost (AF/CB) radiotherapy (RT) and concurrent cisplatin for advanced head and neck squamous cell cancer (HNSCC). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.6014.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/6014

Protocol(s): S0216

Williamson SK, Moon J, Huang CH, Guaglianone P, Wolf GT and Urba SG: A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.6044.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/6044

Protocol(s): S0420

Leukemia, Myelodysplasia, and Transplantation

CALGB

Langer C, Ruppert AS, Radmacher MD, Whitman SP, Paschka P, Baldus CD, Mrózek K, Kolitz JE, Marcucci G, Bloomfield CD: High BAALC expression associates with other molecular prognostic markers, poor outcome and a distinct gene expression signature in cytogenetically normal acute myeloid leukemia (CN AML): A Cancer and Leukemia Group B (CALGB) study. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7013.

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vqnextoid=76f8201eb61a7010VqnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=33770

Protocol(s): CALGB-19808

Marcucci G, Moser B, Blum W, Stock W, Wetzler M, Kolitz JE, Thakuri M, Carter T, Stuart RK, Larson RA: A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7012.

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vqnextoid=76f8201eb61a7010VqnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=30319

Protocol(s): CALGB-10201

Powell BL, Moser B, Stock W, Gallagher RE, William C, Coutre S, Feusner JH, Applebaum FR, Tallman MS, Larson RA: Effect of consolidation with arsenic trioxide (As₂O₃) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.2.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/2

Protocol(s): C9710

Radmacher MD, Marcucci G, Paschka P, Vukosavljevic T, Whitman SP, Ruppert AS, Mrózek K, Kolitz JE, Larson RA, Bloomfield CD: MicroRNA (miR) expression signatures in molecular subsets of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7010.

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/7010

Protocol(s): CALGB-19808

Stock W, Moser BK, Powell BL, Appelbaum F, Tallman M, Larson RA, Feusner J, Bloomfield CD, Willman C, Gallagher RE: Prognostic significance of initial clinical and molecular genetic features of acute promyelocytic leukemia (APL): Results from the North American Intergroup Trial, C9710. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7016.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7016

Protocol(s): C9710

Whitman SP, Ruppert AS, Radmacher MD, Mrozek KA, Paschka P, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD: FLT3 D835/I836 mutations predict worse disease-free survival (DFS) in younger adults with cytogenetically normal acute myeloid leukemia (CN AML) without FLT3 internal tandem duplications (ITD): A Cancer and Leukemia Group B (CALGB) study. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.10532.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/10532

Protocol(s): CALGB-9665, CALGB-19808, CALGB-8461

COG

Dreyer Z, Dinndorf P, Sather H, Hilden JM, Devidas M, Heerema NA, Smith FO, Carroll WL, Reaman GH, Camitta BM: Hematopoietic stem cell transplant (HSCT) versus intensive chemotherapy in infant acute lymphoblastic leukemia (ALL). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.9514.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9514

Protocol(s): P9407

Matloub YH, Angiolillo A, Bostrom B, Stork L, Hunger S, Nachman J, Sather H, La MK, Carroll WL, Gaynon PS: Augmented Berlin-Frankfurt-Muenster (ABFM) regimen for children with standard-risk acute lymphoblastic leukemia (SR-ALL) and slow early response (SER). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.9511.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9511

Protocol(s): CCG-1991

Raetz E, Cairo M, Borowitz M, Blaney S, Krailo M, Leil TA, Goldenberg DM, Wegener WA, Carroll WL, Adamson P: Chemoimmunotherapy reinduction with epratuzumab in children with ALL with marrow relapse: A Children's Oncology Group (COG) pilot study (ADVL04P2). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.9513.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9513

Protocol(s): ADVL04P2

Stock W, Moser BK, Powell BL, Appelbaum F, Tallman M, Larson RA, Feusner J, Bloomfield CD, Willman C, Gallagher RE: Prognostic significance of initial clinical and molecular genetic features of acute promyelocytic leukemia (APL): Results from the North American Intergroup Trial, C9710. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7016.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7016

Protocol(s): C9710

Lymphoma and Plasma Cell Disorders

CALGB

Morrison VA, Weller EA, Habermann TM, Cassileth PA, Cohn J, Gascoyne RD, Woda B, Fisher RI, Peterson BA, Horning SJ: Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 update. *J Clin Oncol* 2007; 25(18S(Jun 20 Suppl)):Abst.8011.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/8011

Protocol(s): E4494

ECOG

Aurora V, Li S, Horning SJ, Variakojis D, Nelson BP, Krajewska M, Habermann TM, Fisher RI, Gascoyne RD, Winter JN: Prognostic significance of p53/p21 expression in DLBCL treated with CHOP or R-CHOP: A correlative study of E4494. *J Clin Oncol* 2007; 25(18S(Jun 20 Suppl)):Abst.8038.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/8038

Protocol(s): E4494

Hochster HS, Weller E, Gascoyne RD, Ryan T, Habermann TM, Gordon LI, Frankel SR, Horning SJ: Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: Results from the ECOG/CALGB intergroup E1496 trial. *J Clin Oncol* 2007; 25(18S(Jun 20 Suppl)):Abst.8004.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/8004

Protocol(s): E1496

Morrison VA, Weller EA, Habermann TM, Cassileth PA, Cohn J, Gascoyne RD, Woda B, Fisher RI, Peterson BA, Horning SJ: Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 update. *J Clin Oncol* 2007; 25(18S(Jun 20 Suppl)):Abst.8011.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/8011

Protocol(s): E4494

Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, Abonour R, Siegel D, Greipp P: Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. *J Clin Oncol* 2007; 25(18S(Jun 20 Suppl)):Abst.LBA8025.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/LBA8025

Protocol(s): E4A03

Lung Cancer

ACOSOG

Hillman SL, Sargent DJ, Bot BM, DeMatteo RP, Perez EA, Ballman KV, Mandrekar SJ: Questionable value of attribution when interpreting adverse event data: A joint evaluation by North Central Cancer Treatment Group (NCCTG) and American College of Surgeons Oncology Group (ACOSOG). *J Clin Oncol* 2007; 25(18S(Jun 20 Suppl)):Abst.6511.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/6511

Protocol(s): NCCTG-97-24-51, ACOSOG-Z9001

CALGB

Green MR, Miller AA, Wang X, Gu L, Vokes EE: Phase II randomized study of dose-dense docetaxel (Doc) and cisplatin (Cis) every two weeks with pegfilgrastim (Pfil) and darbepoetin alfa (Darb) with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (NSCLC): CAL. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7617.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7617

Protocol(s): CALGB-30303

Kelley MJ, Bogart JA, Hodgson LD, Ansari RH, Atkins JN, Wang X, Green MR, Vokes EE: CALGB 30206: Phase II study of induction cisplatin (P) and irinotecan (I) followed by combination carboplatin (C), etoposide (E), and thoracic radiotherapy for limited stage small cell lung cancer. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7565.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7565

Protocol(s): CALGB-30206

Lilenbaum R, Wang X, Gu L, Kirshner J, Vokes EE: Phase II randomized trial of docetaxel plus cetuximab or bortezomib in patients with advanced NSCLC and performance status (PS) 2—CALGB 30402. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7595.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7595

Protocol(s): CALGB-30402

Ready NE, Dudek AZ, Wang X, Graziano SL, Green MR, Vokes EE: CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7563.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7563

Protocol(s): CALGB-30306

ECOG

Kolesar J, Brahmer J, Lee J, Guaglianone P, Patel J, Keppen M, Hidalgo M, Carbone DP, Schiller J: Final results of ECOG 3503: A pilot study to determine if downstream markers of EGFR linked signaling pathways predict response to erlotinib (OSI-774) in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7588.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7588

Protocol(s): E3503

Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler A, Schiller JH, Johnson DH: Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7535.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7535

Protocol(s): E4599

Sandler A, Szwaric S, Dowlati A, Moore DF, Schiller JH: A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7564.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7564

Protocol(s): E3501

Solomon BJ, Roder H, Robert R, Taguchi F, Brahmer J, Joan SH, Duncan MW, Hirsch FR, Bunn PA, Carbone DP: Validation of proteomic classifier for clinical benefit from erlotinib as first line treatment for advanced non-small cell lung cancer (ECOG 3503). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7508.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7508

Protocol(s): E3503

NCCTG

Adjei AA, Molina JR, Hillman SL, Luyun RF, Reuter NF, Rowland KM, Jr., Jett JR, Mandrekar SJ, Schild SE: A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7547.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7547

Protocol(s): N0326

Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Jett JR, Adjei AA: Age, gender, performance status and stage outperformed stage alone in predicting overall survival (OS) in patients with small cell lung cancer: A pooled analysis of 1,623 patients from the North Central Cancer Treatment Group. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7723.

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/7723

Protocol(s): Multiple Trials

Hillman SL, Sargent DJ, Bot BM, DeMatteo RP, Perez EA, Ballman KV, Mandrekar SJ: Questionable value of attribution when interpreting adverse event data: A joint evaluation by North Central Cancer Treatment Group (NCCTG) and American College of Surgeons Oncology Group (ACOSOG). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.6511.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/6511

Protocol(s): NCCTG-97-24-51, ACOSOG-Z9001

Markovic SN, Suman VJ, Schaefer P, Morton R, Rowland KM: Aerosolized sargramostim for the treatment of metastatic melanoma to the lungs. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.8565.

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/8565

Protocol(s): N0071

Schild SE, Mandrekar SJ, Jatoi A, McGinnis WL, Stella PJ, Deming RL, Jett JR, Garces YI, Allen KL, Adjei AA: The value of combined modality therapy in elderly patients with stage III non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.19503.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/19503

Protocol(s): NCCTG-90-24-51

Yang P, Mandrekar S, Hillman S, Allen K, Jett J, Perez E, Adjei A: Glutathione pathway genes predict quality of life (QOL) in lung cancer patients: A NCCTG-97-24-51 based study. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.18037.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/18037

Protocol(s): NCCTG-97-24-51

NCIC Clinical Trials Group

Bezjak A, Lee CW, Ding K, Winton T, Brundage M, Graham B, Whitehead M, Seymour L, Shepherd FA: Quality of life (QOL) impact of adjuvant chemotherapy for early stage non-small cell lung cancer (NSCLC): Final analysis of JBR.10 randomized trial. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7585.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7585

Protocol(s): JBR10

Fruh M, Tribodet H, Pignon J, Winton T, Le Chevalier T, Scagliotti GV, Douillard JY, Seymour L, Spiro SG, Shepherd FA: A pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7553.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7553

Protocol(s): JBR10

Stewart LA, Burdett S, Tierney JF, Pignon J and NSCLC Collaborative Group: Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7552.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7552

Protocol(s): JBR10

Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Whitehead M, Seymour L, Winton T, Shepherd FA: P53 protein over-expression but not p53 gene mutation is a poor prognostic marker and a predictive marker for survival benefit from adjuvant chemotherapy in non-small cell lung cancer (NSCLC) in the JBR.10 Trial. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7577.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7577

Protocol(s): JBR10

RTOG

Blumenschein G, Moughan J, Curran W, Robert F, Fossella F, Werner-Wasik M, Doescher P, Choy H, Komaki R: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (pts) with stage III A/B non-small cell lung cancer (NSCLC): An interim report of the RTOG 0324 trial. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7531.

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vqnextoid=76f8201eb61a7010VqnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=35561

Protocol(s): RTOG-0324

Komaki R, Moughan J, Ettinger D, Videtic G, Bradley J, Glisson B, Choy H: Toxicities in a phase II study of accelerated high dose thoracic radiation therapy (TRT) with concurrent chemotherapy for limited small cell lung cancer (LSCLC) (RTOG 0239). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7717.

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vqnextoid=76f8201eb61a7010VqnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=31584

Protocol(s): RTOG-0239

Lu C, Lee JJ, Komaki R, Herbst R, Evans W, Choy H, Desjardins P, Esparaz BT, Truong M, Fisch M: A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non- small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7527.

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vqnextoid=76f8201eb61a7010VqnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=34110

Protocol(s): RTOG-02-70

Movsas B, Moughan J, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Byhardt R: Randomized trial of amifostine in locally advanced non-small cell lung cancer (NSCLC) patients receiving chemotherapy and hyperfractionated radiation (HRT): Long-term survival results of Radiation Therapy Oncology Group (RTOG) 9801. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7529.

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vqnextoid=76f8201eb61a7010VqnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=30511

Protocol(s): RTOG-98-01

SWOG

Albain KS, Unger J, Gotay CC, Davies AM, Edelman M, Herbst RS, Kelly K, Williamson S, Wozniak AJ, et al.: Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7549.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7549

Protocol(s): S0023, S0342, S0341

Gandara DR, Kawaguchi T, Crowley JJ, Moon J, Kawahara M, Teramukai S, Williamson SK, Furuse K, McLeod HL, et al.: Pharmacogenomic (PG) analysis of Japan-SWOG common arm study in advanced stage non-small cell lung cancer (NSCLC): A model for testing population-related pharmacogenomics. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7500.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7500

Protocol(s): S0003

Herbst RS, Chansky K, Kelly K, Atkins JN, Davies AM, Dakhil SR, Albain KS, Kim ES, Crowley JJ, et al.: A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7545.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7545

Protocol(s): S0342

Hesketh PJ, Chansky K, Wozniak AJ, Mack P, Lara PN, Franklin WA, Hirsch FR, Crowley J and Gandara DR: Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2: A SWOG phase II trial (S0341). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7536.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7536

Protocol(s): S0341

Kelly K, Chansky K, Gaspar LE, Jett JR, Ung Y, Albain KS, Crowley JJ and Gandara DR: Updated analysis of SWOG 0023: A randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7513.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7513

Protocol(s): S0023

Lara PN, Redman M, Lenz H, Gordon M, Shibata T, Fukuda H, Tamura T, Saijo N, Natale R, et al.: Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.7524.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/7524

Protocol(s): S0124

Melanoma/Skin Cancers

ECOG

Stuckert JJ II, Tarhini AA, Lee S, Sander C, Kirkwood JM: Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.8506.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/8506

Protocol(s): E2696

NCCTG

Perez DG, Suman V, Amatruda T, Gornet M, Morton R, Jilani S, Constantinou C, Egner J, Markovic S: Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.8560.

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/8560

Protocol(s): N047A

Rao RD, Allred JB, Windschitl HE, Maples WJ, McWilliams RR, Creagan ET, Kaur JS, Kottchade LA, Gornet MK, Pockaj BA, Markovic SN: N0377: Results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.8530.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/8530

Protocol(s): N0377

Sarcoma/Bone and Soft Tissue Cancers

COG

Leavey P, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J, Bernstein M, Granowetter L, Grier H: Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence. *J Clin Oncol* 2007; 25(18S(Jun 20 Suppl)):Abst.10011.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/10011

Protocol(s): INT0091

ECOG

Von Roenn JH, Lee S, Cianfrocca M, Tulpule A, Scadden D, Aboulafia D, Sparano J: Phase III study of paclitaxel versus pegylated liposomal doxorubicin (PLD) for the treatment of advanced human immunodeficiency virus (HIV)-associated Kaposi's sarcoma (KS): An Eastern Cooperative Oncology Group and AIDS Malignancy Consortium trial. *J Clin Oncol* 2007; 25(18S(Jun 20 Suppl)):Abst.20503.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/20503

Protocol(s): E1D96

SWOG

Van Glabbeke MM, Owzar K, Rankin C, Simes J, Crowley J and GIST Meta-analysis Group (MetaGIST): Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analysis based on 1,640 patients (pts). *J Clin Oncol* 2007; 25(18S(Jun 20 Suppl)):Abst.10004.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/10004

Protocol(s): S0033

Other Cancer

CALGB

Miller AA, Murry DJ, Owzar K, Hollis DR, Abou-Alfa GK, Desai A, Hwang JJ, Villalona-Calero MA, Dees EC, Lewis LD, Ratain MJ: Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301. *J Clin Oncol* 2007; 25(18S(Jun 20 Suppl)):Abst.3538.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/3538

Protocol(s): CALGB-60301

COG

Aplenc R, Strauss LC, Shusterman S, Ingle AM, Luo R, Wright J, Blaney S, Adamson PC: Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: A report from the Children's Oncology Group. *J Clin Oncol* 2007; 25(18S(Jun 20 Suppl)):Abst.14094.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/14094

Protocol(s): ADVL0516

Baker D, Schmidt ML, Cohn S, London W, Buxten A, Sandler A, Shimada H, Matthay K: A phase III trial of biologically-based therapy reduction for intermediate risk neuroblastoma. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.9504.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9504

Protocol(s): A3961

Fouladi M, Park J, Sun J, Fraga C, Ames MM, Stewart CF, Gilbertson RJ, Zweibel J, Adamson P, Blaney S: A phase I trial of vorinostat in children with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.9569.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9569

Protocol(s): ADVL0416

Kreissman S, Villablanca JG, Diller L, London W, Maris JM, Park J, Reynolds CP, von Allmen D, Cohn S, Matthay KK: Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): A Children's Oncology Group (COG A3973) study. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.9505.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9505

Protocol(s): A3973

McGregor LM, Spunt SL, Furman WL, Stewart CF, Krailo M, Speights R, Houghton P, Ivy SP, Blaney S, Adamson P: A phase I study of oxaliplatin (OXA) and irinotecan (IRN) in pediatric patients with refractory solid tumors: A Children's Oncology Group study. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.9546.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9546

Protocol(s): ADVL0415

Perentesis J, Wagner LM, Ames MM, Reid JM, Stewart CF, Ingle AM, Blaney S, Adamson P: Phase I study of oral irinotecan, temozolomide, and vincristine for children with refractory solid tumors: A Children's Oncology Group study. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.9563.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9563

Protocol(s): ADVL0414

ECOG

He Z, Sun Z, Liu G, Manola J, Loehrer P: Prolonged survival in patients with persistently elevated tumor markers after chemotherapy for nonseminomatous germ cell cancer. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.5051.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/5051

Protocol(s): EST-3887, EST-4887

NCCTG

Barton DL, Soori GS, Bauer B, Sloan J, Johnson PA, Figueras C, Duane S, Dakhil S, Liu H, Loprinzi CL: A pilot, multi-dose, placebo-controlled evaluation of american ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N03CA. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.9001.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9001

Protocol(s): N03CA

Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, Beer TM, Perrin N: Prognostic significance of patient-physician disagreement about performance status in patients with advanced cancer. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.9021.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9021

Protocol(s): Multiple Trials

NCI/CTEP Abstracts & Activities

Abstracts with DCTD and DCP Investigators

Anderson BD, Goldberg J, Adler J, Covington L, Olson D, Gordon B, Reaman G, Everett J, Smith M and Christian M: The NCI pediatric central institutional review board (PedCIRB) initiative: Progress and impact. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst. 6632.

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/6632

Aplenc R, Strauss LC, Shusterman S, Ingle AM, Luo R, Wright J, Blaney S, Adamson PC: Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: A report from the Children's Oncology Group. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.14094.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/14094

Denicoff AM, Hopkins JR, Riordan SE, Adler JM, Marinucci DM, Geisen K, Lambersky R, Catalano RB, Mooney MM, Abrams JS: Expanding participation to non-group members in phase III cooperative group treatment trials. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.6533.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/6533

Fouladi M, Park J, Sun J, Fraga C, Ames MM, Stewart CF, Gilbertson RJ, Zweibel J, Adamson P, Blaney S: A phase I trial of vorinostat in children with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.9569.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9569

Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Giannini C, Hardwick JS, Moore DF Jr, Zwiebel JA, Buckner JC: N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM). J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.2004.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/2004

George RE, Lahti J, Ingle M, Krailo M, Blaney S, Adamson P, Murgo A, Kidd VJ, Diller L: Decitabine (DAC) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in relapsed neuroblastoma (NBL): A Children's Oncology Group Study. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.9565.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9565

McGregor LM, Spunt SL, Furman WL, Stewart CF, Krailo M, Speights R, Houghton P, Ivy SP, Blaney S, Adamson P: A phase I study of oxaliplatin (OXA) and irinotecan (IRN) in pediatric patients with refractory solid tumors: A Children's Oncology Group study. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.9546.

http://meeting.jco.org/cgi/content/abstract/25/18_suppl/9546

Smith MA, Maris JM, Keir ST, Lock RB, Carol H, Gorlick R, Kolb EA, Keshelava N, Reynolds CP, et al.: Pediatric preclinical testing program (PPTP) efficacy and pharmacodynamic evaluation of the Hsp90 inhibitor 17-DMAG. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.3735.

http://meeting.jco.org/cqi/content/abstract/25/18_suppl/3575

Trimble EL, Gius D and Harlan LC: Impact of NCI Clinical Announcement upon use of chemoradiation for women with cervical cancer. J Clin Oncol 2007; 25(18S(Jun 20 Suppl)):Abst.5537.

http://meeting.jco.org/cqi/content/abstract/25/18_suppl/5537

DCTD and DCP Activities

Scientific

Dr. J. Abrams (DCTD/CTEP): Chair, Brain Tumor Intergroup meeting. American Society of Clinical Oncology Annual Meeting, Chicago, IL, Jun, 2007.

Dr. A. Martin (DCTD/CTEP): Coordinator, GU Intergroup meeting. American Society of Clinical Oncology Annual Meeting, Chicago, IL, Jun, 2007.

Dr. E. Trimble (DCTD/CTEP): Coordinator and NCI member, Gynecologic Cancer Steering Committee (GCSC) meeting. American Society of Clinical Oncology Annual Meeting, Chicago, IL, Jun, 2007.

Dr. E. Trimble (DCTD/CTEP): Executive Board member, Gynecologic Cancer Intergroup (GCIG) Board meetings and Coordinator, working groups and general assembly. American Society of Clinical Oncology Annual Meeting, Chicago, IL, Jun, 2007.

Dr. J. Zujewski (DCTD/CTEP): Coordinator, the BIG-TBCI meeting on pathological endpoints in breast cancer neoadjuvant trials. American Society of Clinical Oncology Annual Meeting, Chicago, IL, Jun, 2007.

Dr. J. Zujewski (DCTD/CTEP): Coordinator, The North American Breast Cancer Intergroup (TBCI) meeting. American Society of Clinical Oncology Annual Meeting, Chicago, IL, Jun, 2007.

Educational

Grunberg SM, Fisch M and Denicoff A (DCTD/CTEP): Issues in Communication: Presentation of Phase I Trials (ASCO Categorical Course: Optimizing Oncology Care: Symptom Management and Communication Skills, Moderator: von Roenn JH). American Society of Clinical Oncology Annual Meeting, Chicago, IL, Jun, 2007.

Disclaimer: References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References will appear under only one disease heading chosen as the primary disease but will appear under as many Cooperative Group subheadings as is applicable. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may also be included upon agreement and provided the required information is available. Links to online abstracts have been provided where they were available at the time of publication but there is no guarantee that these links will remain active.